Chemical structure of molecule JNJ-63576253 Androgen Receptor Antagonist

oral WT and F877L mut. AR inhibitor

completed Ph. I/II trial in mCPRC

no hepatotox. vs. bioactivated prior lead

J. Med. Chem., Jan. 20, 2021

Janssen R&D, Spring House, PA

The JNJ AR antagonist, JNJ-63576253, is a clinical molecule for prostate cancer that is active against both wild-type androgen receptor as well as the clinically relevant AR mutant, F877L.…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.